Literature DB >> 29063261

[What is new in symptomatic MS treatment: Part 1-introduction and methodical approach, ataxia and tremor].

T Henze1, W Feneberg2, P Flachenecker3, D Seidel4, H Albrecht5, M Starck2, S G Meuth6.   

Abstract

The symptomatic treatment of multiple sclerosis (MS) nowadays is of similar importance as immunotherapy within a comprehensive concept of therapy of this chronic disease, since it contributes considerably to the reduction of disabilities in activities of daily living as well as social and occupational life. Moreover, symptomatic treatment is of great importance for amelioration of quality of life. Since our last survey of symptomatic MS treatment in 2004 and publication of the guidelines of the German Neurological Society and the Klinisches Kompetenznetz Multiple Sklerose (KKN‑MS) in 2014 several developments within the topics of mobility, bladder and sexual function, vision, fatigue, cognition and rehabilitation took place. These new findings together with further aspects of disease measures and overall treatment strategies of the respective symptoms, as well as treatment goals are introduced in a series of six individual contributions. Here, the topic will be introduced, the methodical approach will be explained, and the treatment of ataxia and tremor will be discussed.

Entities:  

Keywords:  Ataxia and tremor; Methods; Multiple sclerosis; Symptomatic treatment

Mesh:

Year:  2017        PMID: 29063261     DOI: 10.1007/s00115-017-0438-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  41 in total

Review 1.  Treatment for ataxia in multiple sclerosis.

Authors:  R J Mills; L Yap; C A Young
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Surgical therapy for multiple sclerosis tremor: a 12-year follow-up study.

Authors:  A Hassan; J E Ahlskog; M Rodriguez; J Y Matsumoto
Journal:  Eur J Neurol       Date:  2012-01-17       Impact factor: 6.089

3.  Isoniazid and action tremor in multiple sclerosis.

Authors:  M Hallett
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-09       Impact factor: 10.154

4.  Failure of ondansetron in treating cerebellar tremor in MS patients--an open-label pilot study.

Authors:  J Gbadamosi; C Buhmann; A Moench; C Heesen
Journal:  Acta Neurol Scand       Date:  2001-11       Impact factor: 3.209

5.  Effects of topiramate in patients with cerebellar tremor.

Authors:  GianPietro Sechi; Virgilio Agnetti; Franca M I Sulas; GianFranco Sau; Davide Corda; Maria G Pitzolu; Giulio Rosati
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-09       Impact factor: 5.067

6.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Authors:  Derick T Wade; Petra Makela; Philip Robson; Heather House; Cynthia Bateman
Journal:  Mult Scler       Date:  2004-08       Impact factor: 6.312

7.  Effects on cognition of stereotactic lesional surgery for the treatment of tremor in multiple sclerosis.

Authors:  Marjan Jahanshahi; Socorro Pieter; Sundus H Alusi; Catherine R G Jones; Scott Glickman; John Stein; Tipu Aziz; Peter G Bain
Journal:  Behav Neurol       Date:  2008       Impact factor: 3.342

8.  A controlled trial of isoniazid therapy for action tremor in multiple sclerosis.

Authors:  C B Bozek; L F Kastrukoff; J M Wright; T L Perry; T A Larsen
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

9.  Tetrahydrocannabinol for tremor in multiple sclerosis.

Authors:  D B Clifford
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

Review 10.  Tremor in multiple sclerosis.

Authors:  Marcus Koch; Jop Mostert; Dorothea Heersema; Jacques De Keyser
Journal:  J Neurol       Date:  2007-02-21       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.